Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES PERSUS PARTNERS IN CONNECTION WITH SALE OF PARTS OF ADDPRO’S OPERATIONS
Mandate

VINGE ADVISES PERSUS PARTNERS IN CONNECTION WITH SALE OF PARTS OF ADDPRO’S OPERATIONS

January 12, 2015

Vinge has advised Perusa Partners in connection with its sale of parts of AddPro the Swedish IT integration company’s operation to the company’s founders and management. Perusa Partners acquired the AddPro group in June 2014. The part of the operation which remains in Perusa Partners’ ownership is Security & Communications, which is currently conducted under the business name Coresec Systems. The operational divisions which were sold are Infrastructure and Applications & Integration.

Vinge’s team consisted of partner Malin Ohlin together with associates Ulrich Ziche, Mårten Svensson, Andrea Jägerstad and Linn Gustavsson. Renegotiation of financing procured in connection with the acquisition in June 2014 was handled by partner Mikael Ståhl together with associate Lin Adelwald.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026